605507 国邦医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.0279.88910.0998.39713.642
总资产报酬率 ROA (%)3.0527.5437.3946.31211.125
投入资产回报率 ROIC (%)3.2718.0817.9626.81611.966

边际利润分析
销售毛利率 (%)23.77426.03225.00023.41027.549
营业利润率 (%)12.43316.03615.19413.12818.404
息税前利润/营业总收入 (%)13.78216.16814.56812.17616.914
净利润/营业总收入 (%)10.86213.60013.25111.40316.092

收益指标分析
经营活动净收益/利润总额(%)95.68395.68499.52199.567101.981
价值变动净收益/利润总额(%)3.8943.1453.0803.3782.327
营业外收支净额/利润总额(%)-0.741-1.339-0.799-0.661-1.665

偿债能力分析
流动比率 (X)2.3323.1822.2972.2222.754
速动比率 (X)1.6592.2571.7641.6631.998
资产负债率 (%)26.19322.11325.30928.22420.884
带息债务/全部投入资本 (%)20.74816.14119.93221.96214.692
股东权益/带息债务 (%)380.592517.736400.511354.226578.533
股东权益/负债合计 (%)281.700352.114294.950254.135378.870
利息保障倍数 (X)9.56947.067-28.781-14.074-14.227

营运能力分析
应收账款周转天数 (天)50.53848.30739.29940.36034.998
存货周转天数 (天)136.920127.093111.304122.036118.058